U.S. anesthesia drugs market to reach $3B+ by 2018: 3 key points

The U.S. anesthesia drugs market is expected to be worth more than $3 billion by 2018, according to a MarketReportsOnline report.

Here are three findings from the report:

 

•    The general intravenous anesthesia drugs market is dominating the U.S. anesthesia drugs market.
•    Propofol and Benzodiazepines Class (Diazepam and Midazolam) are the top contributors to intravenous anesthetic drugs.
•    Baxter International, Endo Health Solutions, AstraZeneca and Abbott Laboratories are four main players, but other companies also play a major role in the market.

More articles on anesthesia:

NAPA Dr. Joseph Marino to study treatment for postoperative pain relief
ASA President Dr. J.P. Abenstein on the physician-led ASC anesthesia team
Dr. Eugene Pereira joins Sarasota Memorial Health Care System

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast